NCT06586164 Enhancing Rehabilitation for Veterans With Serious Mental Illness
| NCT ID | NCT06586164 |
| Status | Recruiting |
| Phase | — |
| Sponsor | VA Office of Research and Development |
| Condition | Schizophrenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-02-25 |
| Primary Completion | 2028-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2025-02-25 with a primary completion date of 2028-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study addresses the critical need for innovative therapeutic interventions in Veterans with serious mental illnesses (SMI) receiving care in VA Psychosocial Rehabilitation and Recovery Centers (PRRCs). The vast majority of individuals with SMI suffer from cognitive impairments, leading to chronic functional disability, and impaired outcomes, causing a significant strain on support networks and the VA healthcare system. This study aims to introduce an innovative mental health therapy, Targeted Cognitive Training (TCT), to Veterans struggling with serious mental illnesses (SMI). TCT works to improve basic sensory information processing and, ultimately, clinical, cognitive, and psychosocial functioning. By using EEG biomarkers to identify Veterans with SMI receiving care within VA Psychosocial Rehabilitation and Recovery Centers who are most likely to benefit from this treatment, and by understanding how best to implement this therapy, the investigators hope to enhance care and improve life quality for Veterans with SMI.
Eligibility Criteria
Inclusion Criteria: * Veterans with SMI (e.g., schizophrenia, schizoaffective disorder, bipolar disorder, PTSD) being treated at PRRCs or co-located rehabilitative services. * Age 18 and 83 years. * Fluency in spoken and written English. * Ability to detect 1000 Hz tones binaurally at a 40-dB sound pressure level. * Ability to see with an acuity of 20/40 with both eyes tested together (corrected if applicable) by a standard printed Snellen eye chart reading card. Exclusion Criteria: * Estimated premorbid IQ below 70, as estimated via the WRAT-4 Reading subtest. * Active substance use other than cannabis within the last 30 days as determined by CPRS review, self- report, or positive urine drug screen (obtained as part of the screening process). * History of significant medical or neurological illness. * Inability to comprehend or provide informed consent.
Contact & Investigator
Gregory Light, PhD
PRINCIPAL INVESTIGATOR
VA San Diego Healthcare System, San Diego, CA
Frequently Asked Questions
Who can join the NCT06586164 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 83 Years, studying Schizophrenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06586164 currently recruiting?
Yes, NCT06586164 is actively recruiting participants. Contact the research team at joyce.sprock@va.gov for enrollment information.
Where is the NCT06586164 trial being conducted?
This trial is being conducted at San Diego, United States.
Who is sponsoring the NCT06586164 clinical trial?
NCT06586164 is sponsored by VA Office of Research and Development. The principal investigator is Gregory Light, PhD at VA San Diego Healthcare System, San Diego, CA. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.